Exact Sciences Corp

More Details of Exact Sciences Corp Company

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Company Info

Company codeEXAS

Company nameExact Sciences Corp

IPO dateJan 30, 2001

Founded at1995

CEOMr. Kevin T. Conroy

Number of employees6900

Security typeOrdinary Share

Fiscal year-endJan 30

Address5505 Endeavor Lane

CityMADISON

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code53719

Phone16082845700

Websitehttps://www.exactsciences.com/

Company codeEXAS

IPO dateJan 30, 2001

Founded at1995

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.43M

+1.26%

Ms. Katherine S. (Kay) Zanotti

Independent Director

70.57K

+9.19%

Mr. Everett V. Cunningham

Executive Vice President

47.61K

-0.28%

Mr. Daniel J. (Dan) Levangie

Independent Director

28.91K

+25.85%

Ms. Shacey Petrovic

Independent Director

23.50K

+33.82%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.05K

+74.44%

Mr. Aaron Bloomer

Chief Financial Officer

13.62K

--

Ms. Kimberly J. (Kim) Popovits

Director

6.39K

--

Mr. James E. Doyle

Lead Independent Director

--

Ms. Kathleen Sebelius

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

1.43M

+1.26%

Ms. Katherine S. (Kay) Zanotti

Independent Director

70.57K

+9.19%

Mr. Everett V. Cunningham

Executive Vice President

47.61K

-0.28%

Mr. Daniel J. (Dan) Levangie

Independent Director

28.91K

+25.85%

Ms. Shacey Petrovic

Independent Director

23.50K

+33.82%

Mr. Brian Baranick

Executive Vice President, General Manager - Precision Oncology

23.05K

+74.44%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Commercial

1.31B

47.44%

Medicare Parts B & C

964.10M

34.95%

Other

296.74M

10.76%

International

189.09M

6.85%

COVID 19 testing

0.00

0.00%

By RegionUSD

Name

Revenue

Proportion

United States (Country)

2.57B

93.15%

Outside of united states

189.09M

6.85%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Commercial

1.31B

47.44%

Medicare Parts B & C

964.10M

34.95%

Other

296.74M

10.76%

International

189.09M

6.85%

COVID 19 testing

0.00

0.00%

Shareholder

Update time: Sat, Apr 26

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Fidelity Management & Research Company LLC

10.15%

Capital World Investors

9.44%

The Vanguard Group, Inc.

9.12%

Wellington Management Company, LLP

6.49%

BlackRock Institutional Trust Company, N.A.

4.13%

Other

60.67%

Shareholder Statistics

Shareholder

Proportion

Fidelity Management & Research Company LLC

10.15%

Capital World Investors

9.44%

The Vanguard Group, Inc.

9.12%

Wellington Management Company, LLP

6.49%

BlackRock Institutional Trust Company, N.A.

4.13%

Other

60.67%

Type

Shareholder

Proportion

Investment Advisor

51.55%

Investment Advisor/Hedge Fund

36.05%

Hedge Fund

6.23%

Research Firm

2.45%

Bank and Trust

1.53%

Pension Fund

1.22%

Individual Investor

1.08%

Sovereign Wealth Fund

0.50%

Private Equity

0.37%

Institutional Shareholding

Update time: Mon, Jan 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

1377

200.62M

108.03%

+569.91K

2024Q4

1411

200.72M

108.09%

-225.66K

2024Q3

1375

190.82M

103.28%

-5.17M

2024Q2

1358

185.25M

100.40%

+6.59M

2024Q1

1347

168.41M

92.78%

-6.10M

2023Q4

1356

165.31M

91.41%

-11.01M

2023Q3

1337

167.70M

92.83%

-6.22M

2023Q2

1354

166.38M

92.24%

-10.65M

2023Q1

1343

167.01M

92.90%

-8.56M

2022Q4

1337

163.71M

92.15%

-9.28M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Fidelity Management & Research Company LLC

18.85M

10.15%

-712.35K

-3.64%

Dec 31, 2024

Capital World Investors

17.54M

9.44%

+1.70M

+10.71%

Dec 31, 2024

The Vanguard Group, Inc.

16.95M

9.12%

-741.47K

-4.19%

Dec 31, 2024

Wellington Management Company, LLP

12.06M

6.49%

-2.27M

-15.86%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

7.66M

4.13%

+245.10K

+3.30%

Dec 31, 2024

State Street Global Advisors (US)

6.23M

3.36%

-447.40K

-6.70%

Dec 31, 2024

T. Rowe Price Associates, Inc.

5.62M

3.03%

+2.48M

+78.79%

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

4.27M

2.3%

+876.99K

+25.85%

Dec 31, 2024

William Blair Investment Management, LLC

3.44M

1.85%

-840.44K

-19.61%

Dec 31, 2024

Geode Capital Management, L.L.C.

3.12M

1.68%

+16.83K

+0.54%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

First Trust Nasdaq Lux Digi Health Solutions ETF

2.94%

First Trust NYSE Arca Biotechnology Index Fund

2.61%

Invesco Biotechnology & Genome ETF

2.34%

SPDR S&P Biotech ETF

2.09%

Nuveen ESG Mid-Cap Growth ETF

1.77%

Franklin Genomic Advancements ETF

1.42%

iShares Health Innovation Active ETF

1.39%

Direxion Daily S&P Biotech Bull 3X Shares

1.33%

ROBO Global Healthcare Technology & Innovation ETF

1.28%

VanEck Biotech ETF

1.17%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proportion2.94%

First Trust NYSE Arca Biotechnology Index Fund

Proportion2.61%

Invesco Biotechnology & Genome ETF

Proportion2.34%

SPDR S&P Biotech ETF

Proportion2.09%

Nuveen ESG Mid-Cap Growth ETF

Proportion1.77%

Franklin Genomic Advancements ETF

Proportion1.42%

iShares Health Innovation Active ETF

Proportion1.39%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion1.33%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.28%

VanEck Biotech ETF

Proportion1.17%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

45.460USD

Exact Sciences Corp

45.460

Overview

Company